106,171 Shares of Boston Scientific Corporation $BSX Acquired by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 106,171 shares of the medical equipment provider’s stock, valued at approximately $4,634,000.

Several other large investors have also added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Boston Scientific in the second quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $2,156,233,000. Janus Henderson Group PLC boosted its holdings in shares of Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after buying an additional 3,907,981 shares in the last quarter. Amundi grew its position in shares of Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock worth $886,213,000 after buying an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after buying an additional 2,856,040 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 1.5%

Shares of Boston Scientific stock opened at $44.67 on Wednesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36. Boston Scientific Corporation has a 52 week low of $39.57 and a 52 week high of $105.65. The stock has a 50 day moving average price of $44.19 and a two-hundred day moving average price of $55.23. The stock has a market capitalization of $64.74 billion, a PE ratio of 18.93, a price-to-earnings-growth ratio of 1.30 and a beta of 0.60.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. During the same period in the prior year, the firm earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 1.4% on a year-over-year basis. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

BSX has been the subject of several research analyst reports. Citigroup lowered their price objective on shares of Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a research note on Thursday, October 29th. The Goldman Sachs Group cut their target price on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. TD Cowen cut shares of Boston Scientific from a “buy” rating to a “hold” rating and reduced their price target for the stock from $56.00 to $46.00 in a report on Friday, October 30th. Canaccord Genuity Group decreased their price target on shares of Boston Scientific from $66.00 to $48.00 and set a “buy” rating for the company in a research note on Thursday, October 29th. Finally, Evercore dropped their price objective on shares of Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $61.43.

Boston Scientific Company Profile

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.